2013-02-12 15:32:06 -

Sobi's interim report for the fourth quarter and full year 2012 will be
published on 21 February 2013 at 8.30 a.m. CET.



Conference call at 2.00 p.m. CET

Financial analysts and media are invited to a telephone conference at 2.00 p.m.
CET the same day, hosted by CEO Geoffrey McDonough, CFO Annika Muskantor and COO
Alan Raffensperger. The presentation will be held in English and can be followed
live or afterwards on our website www.sobi.com. Slides used in the presentation
will be available on our website prior to the telephone conference.



Details for participation
Please call:
SE: +46850556476
UK: +442033645371
US: +18776792993



Yours sincerely,

Jorgen Winroth,
VP Investor Relations
Phone: +46 8 697 20 00



About Sobi
Sobi is an international healthcare company dedicated to bringing innovative
therapies and services to improve the lives of rare disease patients. The
product   portfolio is primarily focused on inflammation and genetic diseases,
with three late stage biological development projects within hemophilia and
neonatology. Sobi also markets more than 40 products for companies in the
specialty and rare disease space. In 2011, Sobi had revenues of SEK 1.9 billion
and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.


Sobi Press Release on February 12, 2013, in PDF format: 
 hugin.info/134557/R/1677450/547048.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1677450]